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Background and Objective: Photodynamic therapy (PDT) treats malignant tumors using
photosensitizers and light. We employed a new pulse laser as the excitation light source
for PDT, i.e. an optical parametric oscillator (OPO) system pumped by a Q-switched
Nd:YAG laser, because it provides extremely high peak power.
Study Design]Materials and Methods: The effects of PDT using the photosensitizer
Photofrin and the new laser were evaluated in 12 patients with early gastric cancer.
Results: Complete responses (CR) were obtained in 75% of 12 assessable patients,
CR was observed in all cases with mucosal carcinoma (response rate 100%).
Regarding toxicity, mild photosensitivity was seen in one case and it lasted several
weeks. The other major side effect was decrease of total protein, which was observed in
six patients (40%), lasting several months. There were no serious abnormalities in symp-
toms or laboratory tests.
Conclusion: We conclude that the YAG-OPO laser is suitable as an excitation light
source for PDT.
Keywords." Endoscopic treatment, YAG-OPO laser, Hematoporphyrin derivative (HpD),
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INTRODUCTION then emits a secondary laser beam of 630nm
wavelength when the concentration of the dye is
Photodynamic therapy (PDT) is a relatively adjusted to 0.4mM. The EDL has the following
recently developed endoscopic method for treat- characteristics: wavelength, 630nm; pulse energy,
ing malignant tumors using a photosensitizer, 4mJ; peak power, 400kW; pulse width, 10ns;
initially hematoporphyrin derivative (HpD), and frequency of repetition: 20, 30 or 40 Hz [6]. It
a laser as the excitation light source [1,2]. The was demonstrated in animal tumors [7], in clini-
principle of this method is to kill malignant cells cal studies on gastric cancer [8], and also theoret-
by photo-chemical reaction rather than heat. ically [9] that a pulse laser with an extremely
Because HpD has a higher affinity for malignant high peak power is superior to a continuous wave
tissue than normal tissue, after intravenous injec- laser in terms of the depth of photodynamic
tion it is taken up and retained longer by malig- action. However, the structure of the EDL is
nant tissue [3]. Thus by using weak laser light to complex and physicians feel it is difficult to use,
irradiate the tumor region, malignant tissue can because it needs exchange of helium gas in the
be destroyed selectively [4]. Photofrin Injection(R) excimer laser and the dye solution in the dye
(PHE) which became commercially available in laser. Moreover, it is clear that tunability to
May 1995 in Japan, is freeze-dried Photofrin II longer wavelengths for new photosensitizers will
manufactured by American Cyanamid Co., New be required in the near future. We therefore car-
York, and is imported by Lederle (Japan)Co., Ltd. ried out a clinical study using a new laser as a
Recently several new kinds of photosensitizers light source for PDT.
such as benzoporphyrin derivative (BPD), meta-
tetrahydroxyphenyl chlorin (mTHPC), mono-L-
aspartyl chlorin (NPe6) and tin ethyl etiopurpurin MATERIALS AND METHODS
(ZnET2) have attracted attention because they
are all superior to PHE in purity, have higher Eligibility Criteria
affinity for malignant tumors and show strong Eligibility criteria included (1) biopsy-proven
absorption at longer wavelengths. Clinical studies early gastric cancer that was evaluated as muco-
on these new drugs have been performed in sev- sal or submucosal invasion, (2) either less than
eral countries. 3cm in diameter or 7cm
2 tumor area, (3) entire
Laser equipment such as the argon dye laser, lesion visible endoscopically, (4)no prior therapy
nitrogen dye laser, gold vapor laser, copper vapor for the targeted tumor lesion, however residual
dye laser and excimer dye laser have also been lesions after endoscopic treatments other than
developed, and have been used clinically in PDT were eligible, (5)informed consent of either
Japan. Among these the excimer dye laser (EDL, patients or their relatives before starting therapy.
model PDT EDL-1, Hamamatsu Photonics, There was no restriction on the age of patients.
Hamamatsu, Japan) was authorized as a light
source for PDT by the Ministry of Welfare of Photosensitizer
Japan in 1994 [5]. The indications of PDT
employing PHE and the EDL are limited to early PHE, which is purified freeze-dried hematopor-
stage lung cancer, early stage esophageal cancer, phyrin derivative for intravenous use, contains
early stage gastric cancer and early stage cancer 75 mg/vial porfimer sodium. The active ingredi-
and dysplasia of the uterine cervix. In the EDL ent, porfimer sodium, consists of a mixture of
an ultraviolet laser beam of 308 nm wavelength, porphyrin oligomers of up to eight porphyrin
which is produced by the XeC1 excimer laser, units. The main ingredient is dihematoporphyrin
pumps the dye laser with Rhodamine 640, which ether/ester.PDT FOR EARLY GASTRIC CANCER 167
Laser Equipment
The laser equipment employed in this trial was
an optical parametric oscillator system pumped
by a Q-switched Nd:YAG laser (YAG-OPO
laser, model iLS-TL-50A, Ishikawajima-Harima
Heavy Industries Co., Ltd. (IHI) Tokyo, Japan).
This laser system consists of a Q-switched
Nd:YAG laser that emits a pulse laser beam
coupled to an optical parametric oscillator sys-
tem. The 1064nm wavelength laser beam of the
Q-switched Nd:YAG laser is pumped by a flash
lamp and is converted into a third harmonic gen-
eration (THG) of 355nm wavelength through
two kinds of nonlinear crystals. The THG pumps
an OPO composed of one set of oscillators and
one crystal. Consequently, two kinds of laser
beams are generated, one is the signal, and the
other is the idler. The wavelengths of the two
laser beams can be changed by tuning the angle
of incidence into the OPO. One of these two
beams is used for photoradiation in PDT. Major
specifications of this system are (1) laser wave-
length: 620-670nm, tuned to 630nm in this trial;
(2) pulse energy: maximum 6mJ, energy used
was 5mJ through 4001am core diameter quartz
fiber; (3) peak power: between 700kW and
1MW; (4) pulse width: 5-8 ns; and (5) pulse
frequency: 25 or 50 Hz, 50 Hz was used in this
trial [10].
PDT Procedure
Patients were intravenously given 2.0mg/kg of
PHE after 75 mg/vial of PHE was dissolved in
30ml of 5% glucose and photoradiation was car-
ried out 48-53 hours later. The entire lesion plus
about a 5mm wide margin was irradiated with
the YAG-OPO laser beam transmitted endoscop-
ically. When the distance between the tumor sur-
face and the fiber tip was 3.1cm and the
diversion angle of the laser beam was 20.5, the
irradiation area was approximately cm2. The ir-
radiation was delivered at a total energy intensity
of more than 60J/cm2. For wider lesions, the
irradiation field was first set on a part of the
lesion, and after delivering the scheduled dose of
light there, the field of irradiation was shifted to
the remaining part, in order to irradiate the
entire region as uniformly as possible. Two hun-
dred forty seconds of irradiation were required to
obtain 60 J with 5mJ of pulse energy, and 50 Hz
of pulse frequency. Assuming that the irradiation
was uniform, the total energy intensity (J/cm2)
was calculated by the following formula"
Total energy intensity (J/cm2)
pulse energy (J/pulse)
pulse frequency (pulse/s)
time(s)/total irradiated area (cm2)
After PDT, the patients were given Hz-receptor
antagonist as prophylactic treatment of the ulcer
that would develop. For safety, patients were
exposed as little as possible to direct sunlight for
at least 4 weeks after PDT, and were recom-
mended to wear a wide-brimmed hat, sunglasses,
sunscreen lotion, long-sleeved shirts, and gloves.
Evaluation of Response
The response to PDT was evaluated by endoscopy
and biopsy 1, 2, and 4 weeks, and 2, 3, and 6
months, and year after PDT, and every 6 months
thereafter. Tumor response to treatment was eval-
uated as complete response (CR): no evidence of
tumor either histologically or endoscopically for
at least 4 weeks, partial response (PR): more than
50% reduction in size of tumor for at least 4
weeks, and no change (NC): no change in size of
tumor. Drugs other than PHE that would affect
tumor response or adverse effects such as anti-
cancer drugs were prohibited during PDT except
for drugs for the treatment of adverse effects.
RESULTS
Patient Characteristics
Fifteen patients were entered from June 1995
through December 1996. Of these 15 patients, 12
were evaluable for response. One ineligible patient168 S. MIMURA et al.
had a lesion of more than 7cm2. One patient
dropped out, because the lesion was judged to be
an advanced gastric cancer by the study commit-
tee. One nonevaluable patient was treated by
microwave coagulation one week after PDT.
The characteristics of the 12 eligible patients
are summarized in Table I. The median age was
68.5 years old, and the median performance
status (ECOG) was 0 (Karnofsky performance
status 100%). Five patients’ lesions were located
in the upper third, six in the middle third, and
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one in the lower third of the stomach. Nine
patients had well-differentiated tubular adeno-
carcinoma, one moderately differentiated tubular
adenocarcinoma, one poorly differentiated adeno-
carcinoma and one signet-ring cell carcinoma.
Median tumor area was 3.8 cm2. Four had muco-
sal carcinomas and eight submucosal carcinomas.
Three had superficial elevated type, two superfi-
cial depressed type without ulceration, and seven
superficial depressed type with ulceration of early
gastric cancer. Eleven patients were ineligible for
laparotomy, because of the liver, lung, cardiovas-
cular or kidney function in 10 patients and old
age in one patient. One patient preferred PDT,
because a small cancer nest was left behind after
an endoscopic mucosal resection at another insti-
tute, and the depth of invasion had been proved
to be mucosal carcinoma in the resected specimen.
CR was obtained in 9 of 12 patients (75%), 7
by the initial PDT, while two required a second
PDT to obtain CR. Three PR cases had charac-
teristics such as submucosal invasion, tumor area
more than 2.1 cm in two cases, and tumor area
more than 4.1 cm
2 in one case. The 9 CR patients
had no relapse between 4 and 20 months, with a
median of 9 months. There were no particular
patient characteristics which seemed to influence
the CR rate, but patients with mucosal carcinoma
had a 100% CR rates as shown in Table II.
Toxicity
Toxicity was evaluated in all 15 patients who
entered the study. The results are summarized in
Table III. The main abnormality on laboratory
tests was decrease of total protein observed in six
patients (40%), who all recovered within several
months with normal diet, except one patient with
liver cirrhosis who required intravenous injection
at 150ml of 25% human albumin. Photosensitiv-
ity, observed in one patient, lasted several weelks.
Decrease of erythrocyte and hemoglobin level
lasted several months in two patients. All these
toxicities were grade or slight. No serious
adverse reactions were seen.PDT FOR EARLY GASTRIC CANCER 169
TABLE II Patient characteristics and response
Characteristics CR PR Relapse
in CR
Sex
Male 7 3 0
Female 2 0 0
Age (years)
50-59 0 0
60-69 4 3 0
70-79 3 0 0
80-89 0 0
Performance status (EOCG)
0 7 2 0
0
2 0 0
3 0 0 0
4 0 0 0
Tumor location
Upper third 4 0
Middle third 4 2 0
Lower third 0 0
Histology
Wel. diff. adenocarcinoma* 8 0
Mod. diff. adenocarcinoma 0 0
Poorly diff. adenocarcinoma* 0 0
Signet-ring cell carcinoma 0 0
Tumor area (cm2)
-1.0 0 0 0
1.1-2.0 0 0
2.1-4.0 4 2 0
4.1-7.0 4 0
Depth of invasion
Mucosal 4 0 0
Submucosal 5 3 0
Gross type
Superficial elevated 2 0
UI(-) 0 Superficial depressed
Superficial depressed UI(+) 6 0
* Well-differentiated tubular adenocarcinoma




TABLE III Side effects
Incidence Grade












Efficacy of PDT Using PHE
and YAG-OPO Laser
In 1996, one of the authors (S. M.) reported the
results of a cooperative clinical trial of PDT for
early gastric cancer in 27 patients using PHE and
an EDL [11]. A CR rate of 88% was obtained,
that is 21 out of 24 patients evaluable for
response, but among the 21 CR, three cases
relapsed. The rate of CR without relapse there-
fore was 75%, i.e. 18 out of 24, while that of this
present study was also 75%, i.e. 9 out of 12
patients evaluable for response. However, accord-
ing to the tumor size, the former study included
10 patients with lesions smaller than cm2, all of
whom CR was obtained, while this study had no
cases with such small lesions. Comparing results
for lesions larger than 2.1 cm2, the rate of CR
without relapse was 58%, i.e. 7 out of 12 in the
former study with the EDL, while it was 73%,
i.e. 8 out of 11 in the present study using the
YAG-OPO laser. Briefly, the CR rates without
relapse in both studies were similar, but in lesions
larger than 2.1 cm2, there was a tendency for the
YAG-OPO laser to be slightly superior to the
EDL as a light source in PDT.
Side Effects
Although the main symptoms reported in the lit-
erature were skin reactions such as photosensitiv-
ity, edema and pigmentation, in the present trial
the only case of facial edema had basked in
direct sunlight 3 weeks after administration of
PHE. Observance of our instructions, which
recommend avoidance of direct sunlight for 4
weeks should prevent such side effects. Another
major side effect was decrease of total protein,
which was first reported in 1985 [12], and was
thought to be caused by protein loss from the
base of the ulcer that developed after PDT and
acute gastritis surrounding the ulcer. The wider
the lesion treated PDT, the greater the likelihood170 S. MIMURA et al.
of a problem, especially in the cases with a
tendency toward hypoalbuminemia before treat-
ment.
Clinical Use of PDT
Surgery is the first treatment of choice for early
gastric cancer. However, although more early
stage cases are now being detected as a result of
improvements in survey and diagnostic tech-
niques, many patients are at high surgical risk due
to coexisting hepatic, cardiovascular and/or pul-
monary diseases. For these patients, endoscopic
treatment is desirable. Several kinds of methods
have been developed for the endoscopic treat-
ment of early gastric cancer, such as endoscopic
mucosectomy, but none of them is effective for
treatment of the depressed type with ulceration
and lesions with submucosal invasion. In the pre-
sent trial using PHE and a YAG-OPO laser, the
rate of CR without relapse was 86% (6/7) in
patients with superficial depressed type with
ulceration in which other endoscopic treatments
were not indicated. Furthermore, in patients with
carcinoma invading the submucosal layer, the
rate of CR without relapse was 63% (5/8). These
results are promising for the treatment of super-
ficial depressed type lesions with ulceration, and
carcinoma invading the submucosal layer.
Concerning lesion size, eligibility criteria in the
present study required either less than 3cm
in diameter or 7 cm
2 of tumor area, based on a
former study using the EDL. However, in one
case of a 79-year-old man, who was ineligible
because of tumor size, CR was achieved with no
relapse. The lesion extended over 19cm2 in the
mucosal layer, located in the middle third of the
stomach on the lesser curvature, the gross type
was superficial elevated type, and the histologic
diagnosis was well-differentiated tubular adeno-
carcinoma. For this lesion, photoradiation with a
YAG-OPO laser was performed at 53h after
administration of PHE, giving 1080 J for 27cm2,
which was calculated as 40 J/cm
2 of total energy
intensity. This result suggests two points, one is
that PDT can cure an extensive lesion spreading
over 19cm2, and the other is that an energy
intensity of only 40J/cm
2 can obtain CR in
mucosal cancer. The former will increase the
indications of PDT for more extensive lesions,
and the latter will also expand it, because the
lower the energy intensity required, the greater
the area that can be treated within a certain peri-
od of time.
The above results suggest that PDT is indi-
cated in cases of superficial depressed carcinoma
including lesions with ulceration. However, the
solitary elevated type can be easily treated by
other endoscopic methods. In addition, PDT is
indicated in cases of carcinoma with submucosal
invasion and it is indicated for patients who are
at poor risk for surgery. Finally, PDT is also
indicated in cases with relatively large superficial
lesions.
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